14 Results for "

acute lymphoid leukemia

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "acute lymphoid leukemia" in MCE Product Catalog:

161
161 Publications Verification
Cat. No.: HY-10087A1
CAS No.: 1093851-28-5
Synonyms: ABT-263 dihydrochloride
Navitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax dihydrochloride triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax dihydrochloride alleviates fibrosis and induces thrombocytopenia. Navitoclax dihydrochloride exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax dihydrochloride can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-129602
CAS No.: 2429877-44-9
Purity:  99.73%
Target:  

PROTACs STAT Apoptosis

Research Areas:  

Cancer

SD-36 is a potent STAT3 PROTAC degrader with a Kd of 44.4 nM and a Ki of 11 nM. SD-36 recruits the cereblon/culin 4A E3 ligase complex to mediate ubiquitination and proteasomal degradation of STAT3, inducing G1 phase cell cycle arrest and apoptosis. SD-36 is useful for research on acute myeloid leukemia, anaplastic large cell lymphoma, and hematopoietic and lymphoid malignancies .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-109038
CAS No.: 509092-16-4
Synonyms: KRP-203 free base
Mocravimod (KRP-203 free base) is a sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod retains T cell effector function. Mocravimod can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13660
CAS No.: 509088-69-1
Purity:  99.68%
Synonyms: KRP-203
Mocravimod (hydrochloride) is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod (hydrochloride) preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod (hydrochloride) significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod (hydrochloride) retains T cell effector function. Mocravimod (hydrochloride) can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10087S
CAS No.: 1217620-38-6
Purity:  99.71%
Navitoclax-d8 is the d8-labeled Navitoclax (HY-10087). Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases .
loading...
    loading...
Cat. No.: HY-155412
CAS No.: 2675452-91-0
Purity:  ≥99.0%
Research Areas:  

Cancer

PFI-6 is a selective MLLT1 and MLLT3 YEATS domain probe with IC50 values of 0.14 μM and 0.16 μM, respectively. PFI-6 is applicable for cancer research .
loading...
    loading...
Cat. No.: HY-10087R
CAS No.: 923564-51-6
Synonyms: ABT-263 (Standard)
Navitoclax (Standard) (ABT-263 (Standard)) is the analytical standard of Navitoclax (HY-10087). This product is intended for research and analytical applications. Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases .
loading...
    loading...
Cat. No.: HY-144779
CAS No.: 3033417-31-8
Purity:  95.33%
Target:  

HDAC Autophagy

Research Areas:  

Cancer

HDAC10-IN-1 (compound 13b) is a potent and highly selective HDAC10 inhibitor, with an IC50 of 58 nM. HDAC10-IN-1 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .
loading...
    loading...
Cat. No.: HY-148817
CAS No.: 824960-50-1
Purity:  97.02%
Target:  

WDR5

Research Areas:  

Cancer

WDR5-0102 is an inhibitor of WDR5. WDR5-0102 specifically targets the WIN site of WDR5, disrupts the WDR5-MLL1 interaction, and reduces the histone methyltransferase activity of MLL1. WDR5-0102 exerts dose-dependent toxicity on MDSC-like cells and reduces their osteopontin levels, while showing extremely low cytotoxicity to pancreatic cancer cells. WDR5-0102 can be used in the research of related diseases such as acute myeloid leukemia, lymphoid leukemia, biphenotypic leukemia and pancreatic cancer .
loading...
    loading...
Cat. No.: HY-E70016
CAS No.: 9027-67-2
Synonyms: TdT
Target:  

DNA/RNA Synthesis

Research Areas:  

Others Cancer

Terminal deoxyribonucleotidyltransferase (TdT) catalyses the condensation of deoxyribonucleotide triphosphates onto the 3' hydroxyl ends of DNA strands and adds N-regions to gene segment junctions during V(D)J recombination. Terminal deoxyribonucleotidyltransferase is expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells .
loading...
    loading...
Cat. No.: HY-144782A
Purity:  ≥95.0%
Target:  

HDAC Autophagy

Research Areas:  

Cancer

HDAC10-IN-2 hydrochloride (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC50 of 20 nM. HDAC10-IN-2 hydrochloride modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .
loading...
    loading...
Cat. No.: HY-153953
CAS No.: 2760536-88-5
Target:  

Bcl-2 Family

Research Areas:  

Cancer

Bcl-2-IN-11 (compound 6) is a potent and selective Bcl-2 activity inhibitor, with an IC50 of 0.9 nM. Bcl-2-IN-11 shows weak inhibition of Bcl-xl (IC50 > 1000 nM). Bcl-2-IN-11 can be used for the research of a variety of cancers caused by abnormal overexpression of Bcl-2 family proteins: especially malignant hematologic diseases of acute lymphoid leukemia, etc. Bcl-2-IN-11 can also avoid toxic side effects caused by Bcl-xl inhibition, such as thrombocytopenia .
loading...
    loading...
Cat. No.: HY-144782
CAS No.: 3033417-22-7
Target:  

HDAC Autophagy

Research Areas:  

Cancer

HDAC10-IN-2 (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC50 of 20 nM. HDAC10-IN-2 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .
loading...
    loading...
Cat. No.: HY-P991425

Research Areas:  

Cardiovascular Disease Cancer

AT-1413 is a monoclonal antibody targeting CD43s that recognizes a unique sialylated CD43 epitope spanning amino acid residues 133-165. AT1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in AML cells, with EC50 values of 1.1 nM and 12.4 nM, respectively. AT-1413 binds to a variety of cancer cells, shows weak binding to non-malignant myeloid cells and endothelial cells, and does not bind to healthy lymphoid cells or normal non-hematopoietic cells. AT1413 clears CD43s-expressing leukemic blasts in vivo without affecting non-malignant myeloid cells. AT-1413 can be used in research related to acute myeloid leukemia, myelodysplastic syndrome, melanoma, and breast cancer .
loading...
    loading...
  • 1